Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

SLXN

SLXN News

Newswire

08:52

Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 in Locally Advanced Pancreatic Cancer.

08:49

Silexion Initiates Regulatory Application for Phase 2/3 Trial of SIL204 in LAPC

09:48

Silexion: Litchfield Hills Initiates Buy Rating, Sets Price Target at $6.

08:06

Silexion receives scientific advice from BfArM for Phase 2/3 clinical trial of SIL204.

08:02

Silexion Therapeutics Receives Positive Regulatory Feedback on Phase 2/3 Trial for Pancreatic Cancer

View More

About SLXN

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More